Latest filing published 22 Jun 2026 for Enliven Therapeutics, Inc., €1.1M.
Insider track record
OrbiMed Genesis Master Fund, L.P.: trading record in brief
OrbiMed Genesis Master Fund, L.P. discloses dealings in Enliven Therapeutics, Inc. to SEC (Form 4). We count 2 filings; the first trade dates from 15 June 2026 and the latest from 22 June 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 22 June 2026, reports a transaction of €1.1M in Enliven Therapeutics, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to OrbiMed Genesis Master Fund, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 26,323 shares@ US$45.960.033% mcap76.1% of flowCommon StockSEC144:0000947871-26-000650
- 9,086 shares@ US$42.360.010% mcap23.9% of flowCommon StockSEC144:0000947871-26-000627
2 of 2 declarations
